Interim report
Page 1
MedPlus Health Services Limited 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyd erabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com October 27, 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Fort, Plot No. C/1, G Block, Mumbai – 400001 Bandra - Kurla Complex Bandra (East), Mumbai – 400051 BSE Scrip Code: 543427 NSE Symbol: MEDPLUS Dear Sir/Madam, Sub: Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations) In furtherance to our letter dated September 28, 2026, and pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regu lations, 2015 ('Listing Regulations'), the Board of Directors of the Company, at their meeting held today i.e., October 27, 2026 considered and approved/ noted the following: 1. Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 along with Limited Review Reports receiv ed from the Statutory Auditors of the Company. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosur e Requirements) Regulations, 2015, the Limited Review Reports received from B S R and Co, the Statutory Auditors of the Company along with Un-audited Standalone and Consolidated Financial Results is enclosed herewith. 2. Allotment of 19,095 Equity Shares under the MedPlus Employees Stock Option Plan , 2021('ESOP,2021') to the eligible employees of the Company/ Group Company. The Detailed disclosure as required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SBEB Regulations') is being sent separately. The meeting commenced at 02:00 PM and concluded at 04:30 PM. The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Kindly take note of the same. For MedPlus Health Services Limited Shrenik Soni Company Secretary & Compliance Officer ICSI M. No. F12400 Encl: a/a
Page 2
B S R and Co Chartered Accountants Salarpuria Knowledge City, Orwell B Wing, 6th Floor, Unit-3, Sy No. 83/1 Plot No. 02, Raidurg Hyderabad — 500 081, India Telephone + 91 407 182 2000 Fax + 91 407 182 2399 Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 September 2026 a.nd year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of MedPlus Health Services Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure Ito the Statement. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Principal Oike: 14th Floor, Central 8 Wing and North C Wing, Nesco IT Pat* 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbal .400063 Page 1 of 3
Page 3
B S R and Co Limited Review Report (Continued) MedPlus Health Services Limited 6. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflects total assets (before consolidation adjustments) of Rs. 1,111.48 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 1,788.05 million and Rs. 3,711.23 million, total net profit after tax (before consolidation adjustments) of Rs. 10.64 million and Rs. 21.37 million and total comprehensive income (before consolidation adjustments) of Rs. 10.64 million and Rs. 21.37 million, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustments) of Rs. 11.13 million for the period from 1 April 2026 to 30 September 2026. as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 7. The Statement includes the interim financial results of nine subsidiaries which have not been reviewed, whose interim financial results reflects total assets (before consolidation adjustments) of Rs. 818.37 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 723.60 million and Rs. 1,494.36 million, total net profit after tax (before consolidation adjustments) of Rs. 3.82 million and Rs. 16.32 million and total comprehensive income (before consolidation adjustments) of Rs. 3.82 million and Rs. 16.32 million, for the quarter ended 30 September 2026 and for the period from 1 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustments) of Rs. 41.54 million for the period from 1 April 2026 to 30 September 2026. as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group. Our conclusion is not modified in respect of this matter. For B S Rand Co Chartered Accountants Firm's Registration No.:128510W Partner Hyderabad Membership No.: 225161 27 October 2026 UDIN:26225161HMMAOK5241 Page 2 of 3
Page 4
B S R and Co Limited Review Report (Continued) MedPlus Health Services Limited Annexure I List of entities included in unaudited consolidated financial results. Sr. No Name of component Relationship 1 MedPlus Health Services Limited Holding Company 2 Optival Health Solutions Private Limited Subsidiary 3 Nova Sud Pharmaceuticals Private Limited Subsidiary 4 VVynclark Pharmaceuticals Private Limited Subsidiary 5 Kalyani Meditimes Private Limited Subsidiary 6 Clearancekart Private Limited Subsidiary 7 Sai Sridhar Pharma Private Limited Subsidiary 8 Venkata Krishna Enterprises Private Limited Subsidiary 9 Shri Banashankari Pharma Private Limited Subsidiary 10 Deccan Medisales Private Limited Subsidiary 11 Sidson Pharma Distributors Private Limited Subsidiary 12 MedPlus Insurance Brokers Private Limited Subsidiary 13 MedPlus Foundation Subsidary Page 3 of 3
Page 5
MedPlus Health Services Limited CIN - L85110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037 Statement of Consolidated Financial Results for the Quarter and Half year ended September 30, 2026 (Rs. in Milions) & No Particula n3 Quarter ended Half year ended Year ended September 30, 2026 June 30, 2026 September 30, 2025 September 30, 2026 September 30. 2025 March 31, 2026 Unaudited Unaudited . Unaudited Unaudited Unaudited Audited Income Revenue from operations 20,371.08 18,796.00 16,793.29 39,167.08 32,219.63 68,924.66 Other income 205.43 198.26 174.69 403.69 324.88 713.24 I Total income 20,576.51 18,994.26 16,967.98 39,570.77 32,544.51 69,637.90 Expenses Cost of materials consumed 212.57 206.64 234.06 419.21 425.86 887.30 Purchases of stock-in-trade 15,887.38 14,590.48 12,208.98 30,477.86 22,738.46 50,304.70 Changes in inventories of finished goods, work-in-progress and stock-in-trade (837.36) (604.23) (40.53) (1,441.59) 635.55 (345.93) Employee benefits expense 2,500.35 2,419.06 2,133.22 4,919.41 4,137.63 8,845.28 Finance costs 366.18 332.70 288.19 898.88 581.84 1,204.93 Depreciation end amortisation expense 838.33 779.21 685.62 1,617.54 1,341.80 2,828.68 Other expenses 907.59 851.63 769.09 1,759.22 1,486.36 3,159.64 It Total expenses 19,875.04 18,575.49 16,278.63 38,450.53 31,327.50 66,884.60 III Profit before tax (I-11) 701.47 418.77 689.35 1,120.24 1,217.01 2,753.30 Tax expense - Current tax expense 191.08 114.87 202.30 305.95 346.22 776.63 - Deferred tax benefit (50.30) (27.77) (67.97) (78.07) • (107.66) (219.39) IV Total tax expense 140.78 87.10 134.33 227.88 238.56 557.24 V Net profit after tax (III-IV) 560.69 331.67 555.02 892.36 978.45 2,196.06 Other comprehensive income (OCI) (i) Items that will not be reclassified to profit or loss - Re-measurement gain on employee defined benefit plan 8.49 - - 8.49 26.91 (ii) Income tax relating to items that will not be reclassified to profit or loss (1.43) - (1.43) - (5.20) VI Other comprehensive Income for the period/year, net of tax 7.06 - - 7.06 - 21.71 VII Total comprehensive income for the period/year (V+VI) 567.75 331.67 555.02 899.42 978.45 2,217.77 VIII Profit for the period/year attributable to: Shareholders of tho Company 560.75 331.76 555.01 892.51 978.59 2.196.49 Non-controlling interest (0.06) (0.09) 0.01 (0.15) (0.14) (0.43) 560.69 331.67 . 555.02 892.36 978.45 2,196.06 IX Other comprehensive income for the period/year attributable to: Shareholders of the Company 7.06 - - 7.06 - 21.71 Non-controlling interest 0.00 - - 0.00 - 0.00 7.06 - - 7.06 - 21.71 X Total comprehensive income attributable to: . Shareholders of the Company 567.81 331.76 555.01 899.57 978.59 2,218.20 Non-controlling interest (0.06) (0.09) 0.01 (0.15) (0.14) (0.43) 567.75 331.67 555.02 899.42 978.45 2,217.77 XI Paid-up Capital Equity share capital 240.27 240.27 239.64 240.27 239.64 240.11 XII Other Equity 19,513.48 XIII Earnings per equity share (refer note 4) Basic EPS (In absolute Rs) 4.73 2.76 4.63 7.49 8.17 18.33 Diluted EPS (In absolute Rs) 4.72 2.76 4.62 7.48 8.15 18.29 XIV Face value per share Equity shares (In absolute Rs) 2.00 2.00 2.00 2.00 2.00 2.00
Page 6
Segment information under Regulation 33 of the SEBI (Listing Qbligations and Disclosure Requirements) Regulations, 2015 • for the Quarter and half year ended September 30, 2026 (Rs. In Millions) Quarter Ended I Half year ended Year Ended ' September 30, June 30, S ereptemb 30, September 30, September 30, March 31, Particulars 2028 2026 2025 2026 , 2025 2028 Unaudited Unaudited Unaudited L Unaudited Unaudited Audited 1. Segment revenue a. Retail - 19,957.68 18,423.92 16,456.41 38,381.60 31,577.60 67,601.06 b. Diagnostic services 410.54 370.76 332.50 781.30 635.40 1,309.87 c. Others 2.86 1.32 4.38 4.18 6.63 13.73 Total revenue from operations 20,371.08 18,796.00 16,793.29 39,167.08 32,219.63 68,924.66 2. Segment results profit / (loss) a. Retail 557.56 315.63 592.04 873.19 1,041.58 2,388.11 b. Diagnostic services 49.30 23.24 2.07 72.54 2.84 17.40 c. Others 1.74 (0.34) 3.09 1.40 4,16 6.72 Total 608.60 338.53 597.20 947.13 1,048.58 2,412.23 Add/(Less): Unallocable Finance cost (0.18) (0.05) 0.16 (0.23) (0.11) (0.49) Add: Unallocable other income 93.05 80.29 91.99 173.34 168.54 341.56 Total profit before tax 701.47 418.77 689.35 1,120.24 1,217.01 2,753.30 3. Segment assets a. Retail 33,976.25 31,919.79 27,327.68 33,976.25 27,327.68 31,097.74 b. Diagnostic services 1,469.22 1,380.92 1,437.41 1,469.22 1,437.41 1,377.34 c. Others 2.38 3.63 5.38 2.38 5.38 9.12 d. Unallocated 6,530.44 7,126.66 6,951.69 6,530.44 6,951.69 6,841.06 Total assets 41,978.29 40,431.00 35,722.16 41,978.29 35,722.16 39,325.26 4. Segment liabilities a. Retail 20,149.07 19°,247.99 16,261.06 20,149.07 16,261.06 18,566.31 b. Diagnostic services 1,151.57 1,074.70 1,016.67 1,151.57 1,016.67 1,011.00 c. Others 2.09 1.40 1.19 2.09 1.19 1.41 Total liabilities 21,302.73 20,324.09 17,278.92 21,302.73 17,278.92 19,578.72
Page 7
(Rs. in Millions) S.No. Particulars As at September 30, 2026 (Unaudited) As at March 31, 2026 (Audited ASSETS Non-current assets Property, plant and equipment 3,439.50 3,183.61 Capital work-in-progress 379.10 319.80 Right-of-use assets 13,267.32 12,268.37 Goodwill 414.51 414.51 Other intangible assets 58.87 78.79 Financial assets Other financial assets 1,131.13 1,044.16 Deferred tax assets (net) 1,289.12 1,212.48 Other tax assets (net) 154.08 91.10 Other non-current assets 55.75 25.94 20,189.38 18,638.76 Current assets Inventories 15,210.85 13,816.94 Financial assets Investments 817.80 - Trade receivables 385.37 269.59 Cash and cash equivalents 1,453.43 1,984.12 Bank balances other than cash and cash equivalents 1,354.64 2,637.50 Other financial assets 1,948.06 1,507.86 Current tax assets (net) 0.06 0.42 Other current assets 618.70 470.07 21,788.91 20,686.50 Total Assets 41,978.29 39,325.26 EQUITY AND LIABILITIES II Equity Equity share capital 240.27 240.11 Other equity 20,442.49 19,513.48 Total equity attributable to the owners of the Company 20,682.76 19,753.59 Non-controlling interest (7.20) (7.05) Total Equity 20,675.56 19,746.54 III Liabilities Non-current liabilities Financial liabilities Lease liabilities 13,355.51 12,331.24 Other financial liabilities 10.14 18.50 Provisions 249.47 336.07 13,615.12 12,685.81 Current liabilities Financial liabilities Lease liabilities 2,134.05 1,912.59 Trade payables - Total outstanding dues of micro and small enterprises 217.77 307.49 - Total outstanding dues of creditors other than micro enterprises and small enterprises 3,423.87 2,762.01 Other financial liabilities 618.92 799.58 Other current liabilities 187.88 179.52 Contract liabilities 476.37 410.82 Provisions 581.38 492.60 Current tax liabilities (net) 47.37 28.30 7,687.61 6,892.91 Total Liabilities 21,302.73 19,578.72 Total Equity and Liabilities 41,978.29 39,325.26 , HYDERABAL 0-• MedPlus Health Services Limited CIN - L85110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad Statement of Consolidated Assets and Liabilities
Page 8
MedPlus Health Services Limited CIN - L85110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037 Consolidated Statement of Cash Flows (Rs. in Millions) S.No Particulars For the hair year ended September 30, 2026 (Unaudited) For the half year ended September 30, 2025 (Unaudited) I Cash flow from operating activities Profit before tax • • 1,120.24 1,217.01 Adjustments for: Depreciation of property, plant and equipment 422.41 365.66 Amortisation of intangible assets 20.01 17.37 Depreciation of right-of-use assets 1,175.12 958.77 Provision for gratuity and leave benefits 187.71 136.44 Loss allowance on doubtful debts, deposits and advances 3.00 3.43 Finance costs 0.23 0.51 Interest on lease liabilities 698.65 561.33 Loss on sale/ discard of property, plant and equipment 8.41 1.08 Advances/debts written off 0.22 1.40 Interest income (199.15) (210.82) Gain on sale of current investments (net) (15.36) - Change in fair value of financial assets (7.80) - Employees stock option compensation expenses (0.64) 21.46 Gain on de-recognition of right-of-use assets (23.56) (32.16) Liabilities no longer required written back (2.78) (0.82) Operating profit before working capital changes 3,386.71 3,040.66 Movement in working capital: (Increase) / decrease in inventories (1,393.91) 643.59 Decrease! (increase) in non-current financial assets 56.32 (108.52) Increase in current financial assets (209.45) (26.75) Increase in other assets (147.73) (251.52) Increase in financial liabilities 384.20 183.56 Increase in other current liabilities 73.92 73.42 Decrease in provisions (178.50) (79.68) Cash generated from operations 1,971.56 3,474.76 Income tax paid (net) (349.48) (321.82) Net cash generated from operating activities (A) 1,622.08 3,152.94 II Cash flow from investing activities Purchase of property, plant and equipment and intangible assets including capital work-in-progress, capital advances and capital creditors (774.92) (427.71) Proceeds from sale of property, plant and equipment 0.90 2.95 Acquisition of right-of-use asset (27.69) (19.57) Investment in Mutual funds (5,366.96) Proceeds from sale of Investment in Mutual funds 4,572.32 Proceeds from maturity of bank deposits 4,691.67 4,805.01 Investment in bank deposits (3,921.21) (5,220.83) Interest received 169.50 160.03 Net cash flows used in investing activities (B) (656.39) (700.12) III Cash flow from financing activities Proceeds from issue of equity shares under employee stock option compensation plan 30.58 44.28 Principal repayment of lease liabilities (828.08) (697.98) Interest payment on lease liabilities (698.65) (561.33) Interest paid (0.23) (0.51) Net cash flows used in financing activities (C) (1,496.38) (1,215.54) Net (decrease)/Increase In cash and cash equivalents (A+B+C) (530.69) 1,237.28 Cash and cash equivalents at the beginning of the period 1,984.12 860.52 Cash and cash equivalents at the end of the period 1,453.43 2,097.80 Components of cash and cash equivalents Cash on hand 92.21 95.32 Deposits with original maturity of less than three months 1,071.30 1,731.76 Balances in wallets 159.94 101.99 Balance with banks in current accounts 129.98 168.73 Total cash and cash equivalents 1,453.43 2,097.80 01N HYDERABA', „ ' r--1
Page 9
Notes to the consolidated financial results: 1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('the Company') and its subsidiaries (together referred as 'the Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 27, 2026. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same. 2. During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes', effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment. As a result of this plan amendment, the Group's defined benefit obligation and defined benefit contribution increased by Rs. 34.26 million and Rs. 31.06 million respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss in the previous year. The Group continues to monitor the Central / State Rules as notified and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 3. During the period, the Company incorporated a wholly owned subsidiary, MedPlus Foundation, on May 06, 2026. The financial information of the said subsidiary has been consolidated in these financial results from the date of incorporation, in accordance with the applicable accounting standards. 4. The earnings per equity share for the quarters and half year are not annualised. 5. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. DEP,NBA G. Madhukar Reddy \--A\ Managing Director & Chief Executive Officer DIN: 00098097 Place: Hyderabad Date: October 27, 2026 For and on behalf of the Board of Directors of MedPlus Health Servi es Limited / 4'41
Page 10
B S R and Co Chartered Accountants Salarpuria Knowledge City, Orwell B Wing, 6th Floor, Unit-3, Sy No. 83/1 Plot No. 02, Raidurg Hyderabad — 500 081, India Telephone + 91 407 182 2000 Fax + 91 407 182 2399 Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of MedPlus Health Services Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1.April 2026 to 30 September 2026 ("the Statement") (in which are included interim financial information of Medplus Employees Benefit Trust ("Trust")). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it Principal Office: 14th Floor, Central B Wng and North C Wing, Nesco IT Park 4, Nesco Center, Westem Express Highway, Goregaon (East), Mumbal - 400063 Page 1 of 2
Page 11
B S R and Co Limited Review Report (Continued) MedPlus Health Services Limited contains any material misstatement. For B S R and Co Chartered Accountants Firm's Registration No.:1 10VV R. Vivek Partner Hyderabad Membership No.: 225161 27 October 2026 UDIN:262251611NSJMUY7233 Page 2 of 2
Page 12
MedPlus Health Services Limited CIN - 185110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037 Statement of Standalone Financial Results for the Quarter and Half year ended September 30. 2026 (Rs. in Millions) S. No Particulars Quarter ended Half year ended Year ended September 30, 2026 I June 30, 2026 September 30 2025 September 30 2026 September 30, 2025 March 31, 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income Revenue from operations 2,800.62 2,226.43 2,056.48 5,027.05 8,895.29 8,605.66 Other income 40.43 32.66 29.38 73.09 55.83 107.66 I Total income 2,841.05 2,259.09 2,085.86 5,100.14 3,951.12 8,713.32 Expenses Cost of materials consumed -- 189.00 189.21 234.06 378.21 425.86 812.41 Purchases of stock-in-trade 1,993.78 1,496.24 1,314.07 3,490.02 2,489.27 5,703.85 Changes in inventories of finished goods, work-in-progress and stock-in-trade (66.74) (5.09) (3.75) (71.83) 1.23 7.19 Employee benefits expense 141.59 137.19 132.61 278.78 255.25 542.99 Finance costs 27.95 22.21 23.70 50.16 45.22 83.14 Depreciation and amortisation expense 78.58 69.62 70.37 148.20 137.58 263.86 Other expenses 124.41 119.54 108.67 243.95 213.80 468.15 II Total expenses 2,488.57 2,028.92 1,879.73 4,517.49 3,568.21 7,881.59 III Profit before tax (I-II) 352.48 230.17 206.13 582.65 382.91 831.73 Tax expense - Current tax expense 91.65 64.85 53.79 156.50 100.70 226.14 - Deferred tax benefit (2.18) 9.19) (3.97) (11.37) (9.43) (18.53) IV Total tax expense 89.47 55.66 49.82 145.13 91.27 207.61 V Net profit after tax (III-IV) 263.01 174.51 156.31 437.52 291.64 624.12 Other comprehensive (loss) / Income (i) Items that will not be reclassified to profit or loss - Re-measurement (loss)/gain on employee defined benefit plan (1.04) 4.94 (1.04) 0.26 (ii) Income tax relating to items that will not be reclassified to profit or loss 0.26 (1.19) VI Other comprehensive (loss) / Income for the period / year. net of tax (0.78) (0.78) 3.75 VII Total comprehensive income for the period! year (V+VI) 262.23 174.51 156.31 436.74 291.64 627.87 VIII Paid-up capital Equity share capital 240.27 240.27 239.64 240.27 239.64 240.11 IX Other Equity 12,921.02 X Earnings per equity share (refer note 4) Basic (In absolute Rs.) 2.19 1.45 1.31 3.64 2.44 5.21 Diluted (In absolute Rs.) 2.19 1.45 1.30 3.64 2.43 520 XI Face value per share Equity shares (In absolute Rs.) 2.00 2.00 2.00 2.00 2.00 2.00 CO /HYDERAB/Al. \Lc: ,
Page 13
MedPlus Health Services Limited CIN - L85110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037 Statement of Standalone Assets and Liabilities (Rs. in Millions) S.No. Particulars As at September 30, 2026 (Unaudited) As at March 31, 2026 Audited) I ASSETS Non-Current Assets Property, plant and equipment 857.67 911.04 Capital work-in-progress 42.96 17.35 Right-of-use assets 953.20 748.98 Other intangible assets 5.04 9.22 Financial assets Investments 9,306.99 9,306.44 Other financial assets 204.95 43.50 Deferred tax assets (net) 64.94 53.31 Other tax assets (net) 8.53 6.44 Other non-current assets 25.36 2.12 11,469.64 11,098.40 Current Assets Inventories 296.61 267.71 Financial assets Investments 817.80 - Trade receivables 918.11 1,326.06 Cash and cash equivalents 769.47 464.53 Bank balances other than cash and cash equivalents 482.45 925.86 Other financial assets 449.55 470.76 Other current assets 121.09 96.63 3,855.08 3,551.55 Total Assets 15,324.72 14,649.95 EQUITY AND LIABILITIES II Equity Equity share capital 240.27 240.11 Other equity 13,387.56 12,921.02 Total Equity 13,627.83 13,161.13 III Liabilities Non Current Liabilities Financial liabilities Lease liabilities 1,048.87 842.72 Provisions 0.25 11.13 1,049.12 853.85 Current Liabilities Financial liabilities Lease liabilities 91.94 72.75 Trade payables - Total outstanding dues of micro and small enterprises 49.82 70.53 - Total outstanding dues of creditors other than micro and small enterprises 264.87 269.80 Other financial liabilities 47.40 49.55 Other current liabilities 14.52 22.15 Contract liabilities 124.35 110.95 Provisions 39.62 39.24 Current tax liabilities (net) 15.25 - 647.77 • 634.97 Total Liabilities 1,696.89 1,488.82 Total Equity and Liabilities 15,324.72 14,649.95 N /
Page 14
MedPlus Health Services Limited CIN - L85110TG2006PLC051845 Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037 Standalone Statement of Cash Flows (Rs. in Millions) S.No. Particulars For the Half year ended September 30. 2026 (Unaudited) For the Half year ended September 30, 2025 (Unaudited) I Cash flow from operating activities Profit before tax 582.65 382.91 Adjustment for: Depreciation of property, plant and equipment 80.68 79:72 Amortisation of right-of-use assets 67.54 57.87 Provision for employee benefits 7.88 10.80 Advances/debts written off 0.03 0.07 Loss on sale of property, plant and equipment 1.11 - Interest on lease liability 50.16 45.22 Interest income (52.06) (43.69) Liabilities no longer required written back (1.00) 0.17 Profit on sale of investments (2.49) Change in fair value of financial assets (7.80) - Gain on de-recognition of right-of-use assets (1.07) (3.74) Employees stock option compensation expenses (1.07) 3.58 Operating profit before working capital changes 724.56 532.91 Movement in working capital: . (Increase)! decrease in inventories (28.91) 5.70 Increase in non-current financial assets (7.05) (2.56) Decrease / (Increase) in current financial assets 411.25 (43.31) Increase in other assets (24.33) (67.11) Decrease in current financial liabilities (26.01) (140.85) Increase in other current liabilities 5.77 9.01 Decrease in provisions (19.43) (4.46) Cash generated from operations 1,035.85 289.33 Income tax paid (net) (143.34) (94.56) Net cash generated from operating activities (A) 892.51 194.77 II Cash flow from investing activities Purchase of property, plant and equipment and intangible assets including (73.97) (28.09) capital work-in-progress, capital advances and capital creditors , Investment in subsidary (0.10) .. Investment in Mutual funds (1,566.00) Proceeds from sale of investment in Mutual funds 758.49 - Acquisition of right-of-use asset (7.26) (2.06) Investment in bank deposits (1,549.30) (941.25) Proceeds from maturity of bank deposits 1,859.22 841.20 Interest received 47.11 36.88 Net cash flows used in investing activities (B) (531.81) (93.32) III Cash flows from financing activities Proceeds from issue of equity shares under employee stock option compensation plan 30.58 44.28 Interest payment on lease liabilities (50.17) (45.22) Principal repayment of lease liabilities (36.17) (34.10) Net cash flows used in financing activities (C) (55.76) (35.04) Net increase in cash and cash equivalents (A+B+C) . 304.94 66.41 Cash and cash equivalents at the beginning of the period 464.53 113.00 Cash and cash equivalents at the end of the period 769.47 179.41 Components of cash and cash equivalents Cash on hand 0.62 0.39 Bank deposits with original maturity of less than three months 747.21 ' 162.08 Balance with wallets 4.18 2.27 Balance with banks in current accounts 17.46 14.67 Total cash and cash equivalents 769.47 179.41
Page 15
Notes to the standalone financial results: 1. The above unaudited standalone financial results of MedPlus Health Services Limited ('the Company') have been prepared in accordance with Indian Accounting Standards ('Ind As.) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 27, 2026. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same. 2. During the year ended March 31, 2026, the Central Government of India notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the New Labour Codes', effective from November 21, 2025 primarily impacting the wage definition to be considered for the purpose of defined benefit obligation relating to gratuity and defined benefit contribution relating to leave encashment. As a result of this plan amendment, the Company's defined benefit obligation and defined benefit contribution increased by Rs.1.58 million and Rs. 0.47 million respectively during the year ended March 31, 2026. A corresponding past service cost was recognized in the statement of profit and loss in the previous year. The Company continues to monitor the Central / State Rules as notified and darifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information as part of the consolidated financial results. 4. The earnings per equity share for the quarters and half year are not annualised. 5. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services L"ted G. Madhuk Managing Director & Chief executiv t*, DIN: 00098097 / -4= ,,-;,:\ \ D HYDERABAL , w \ , co i- I Place: Hyderabad ‘ \,..-c). •-:7'../ Date: October 27, 2026 ,